AU629237B2 - Recombinant fusion proteins for altering hormone secretion - Google Patents
Recombinant fusion proteins for altering hormone secretion Download PDFInfo
- Publication number
- AU629237B2 AU629237B2 AU40761/89A AU4076189A AU629237B2 AU 629237 B2 AU629237 B2 AU 629237B2 AU 40761/89 A AU40761/89 A AU 40761/89A AU 4076189 A AU4076189 A AU 4076189A AU 629237 B2 AU629237 B2 AU 629237B2
- Authority
- AU
- Australia
- Prior art keywords
- fusion protein
- protein
- lhrh
- gene
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940088597 hormone Drugs 0.000 title claims description 9
- 239000005556 hormone Substances 0.000 title claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 8
- 230000028327 secretion Effects 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108700012941 GNRH1 Proteins 0.000 claims description 40
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 35
- 230000000890 antigenic effect Effects 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 241000701822 Bovine papillomavirus Species 0.000 claims description 4
- 108090000157 Metallothionein Proteins 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 2
- 102000003792 Metallothionein Human genes 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 102000006771 Gonadotropins Human genes 0.000 description 8
- 108010086677 Gonadotropins Proteins 0.000 description 8
- 239000002622 gonadotropin Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 101710166678 50S ribosomal protein L28, chloroplastic Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001817 pituitary effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002710 gonadal effect Effects 0.000 description 4
- 229940094892 gonadotropins Drugs 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008238 LHRH Receptors Human genes 0.000 description 3
- 108010021290 LHRH Receptors Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000282324 Felis Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000002474 gonadorelin antagonist Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101500023489 Lithobates catesbeianus Gonadoliberin-1 Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000031271 Unwanted pregnancy Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000028892 negative regulation of gonadotropin secretion Effects 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
OPI DATE 23/03/90 APPLN. ID 40761 89
PCT
AOJP DATI6r4/i 2 PcUNUdZR PCT/EP89/01013
INTERNATIONAL
Y (PCT) (51) Internatior.al Patent Classification (11) Internatioal Pulication Number: WO 90/02187 C12N 15/62 C12N 15/16 Al A61K 39/385 (43) International Publication Date: 8 March 1990 (08.03.90) (21) International Application Number: (22) International Filing Date: 2 Priority data: 246,558 30 Augus PCT/EP89/01013 29 August 1989 (29.08.89) (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR. LU (European patent), NL (European patent). NO. SE (European patent).
Published With international search report.
Before the expiration of the time limit Jor amending the claims and to be republished in the event 9f the receipt of amendments.
t 1988 (30.08.88) (71) Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; John B. Gorsiraweg 6, Curacao (AN).
(72) Inventors: CHAPPEL, Scott, C. 39 Hancock Street, Boston, MA 02114 NUGENT, Noreen, P. 38 Westgate Road, Framingham, MA 01701 (US).
(74)Agent: RITTER, Stephen, David; Mathys Squire, Fleet Street, London EC4Y lAY (GB).
(54)Title: RECOMBINANT FUSION PROTEINS FOR ALTERING HORMONE SECRETION I T (57) Abstract H 3 N L I d Coo A recombinant fusion protein, resulting from the expression, of two genes regulated by single promoter, having the effect of altering hormone secretion when administered in a therapeutically effective dose. One gene codes for the production of a highly antigenic, hydrophilic protein, such as hepatitis B surface antigen, and the other gene codes for a peptide which alone is not substantially antigenic, such as luteinizing hormone releasing hormone.
Bam Ava Ava Xba Ava I I I I I HbSA
I
L Bam Ava Ava Xba 1 1 I I HbSA+ LHRH I .I r tl PCT/EP89/01013 WO 90/02187 suggested to use non-antigenic peptides in such a fusion protein i nr or t- Ih hl nrlii 4-V 'n r r F 4 4- 4 -4- WO 90/02187 PCT/EP89/01013 RECOMBINANT FUSION PROTEINS FOR ALTERING HORMONE SECRETION Field of Invention This invention relates to the production of fusion proteins produced by recombinant DNA technology and used as active immunogens against peptides which are not inherently antigenic.
By combining the gene for a highly antigenic protein, such as the hepatitis surface antigen (KBsAg), and the cDNA encoding for a protein, portion of a proteinj r-peptide which is not inherently antigenic, a fusion protein may be expressed. Following injection of this highly antigenic fusion protein, polyclonal antibodies are produced that are directed against both the highly antigenic protein and the protein of interest. Thus, this technology provides a method to immunoneutralize endogenously produ:-[', hormones and could be used to induce an infertile state or inhibit the hormone dependent growth of rapidly multiplying tissue.
Background of the Invention As a result of the pioneering work of Guil?'min, Schally and coworkers during the late 1960's, it has become evident that the hypothalamic decapeptide, luteinizing hormone releasing hormone (LHRH) is intimately involved in the initiation and maintenance of reproductive competence in all mammals. Disruption or 'destruction of neuronal pathways involved in the synthesis of LHRH or its transport to the capillary network that provides humoral communication between the hypothalamus and pituitary results in a I SUBSTITUTE
SHEET
WO 90/02187 PCT/EP89/01013 reduction in gonadotropin synthesis and release and infertility (Kalra and Kalra, Endocrine Reviews 4:311, 1983).
Similarly, reductions in LHRH-pituitary interactions may be elicited through the administration of long-acting competitive antagonists of LHRH. These synthetic peptides bind to the pituitary LHRH receptor but do not stimulate post-receptor intracellular activities. Due to their unusually long receptor occupancy, caused by their resistance to proteolytic inactivation, these peptides induce a state of pituitary insensitivity to LHRH due to down regulation of LHRH receptor number. This pharmacologic reduction in pituitary stimulation by LHRH antagonists results in a reduction in gonadotropin release and infertility (Labrie et al [eds] LHRH and its analogs. Amsterdam: Elsevier Scientific Publishers. 1984).
Another method employed to disrupt LHRH-pituitary interactions has been the production of antibodies against LHRH.
Active LHRH immunization has been accomplished in a number of species including the rat (Fraser et al; J. Endocrinology 63:399, 1974), rabbit (Arimura et al; Endocrinology 93:1092, 1973), ewe (Clarke et al: J. Endocrinol 78:39, 1978) and rhesus monkey (Chappel et al; Biol. Reprod. 22:333, 1980). In all species, active immunization against LHRH results in a loss of reproductive function characterized by low serum concentrations of gonadotropins and gonadal steroids and impairments in gametogenesis. Due to the extremely short half-life of LHRH in an animal (less than five minutes), most active immunization has been performed with LHRH conjugated to much larger molecules., such as bovine serum 'SUBSTITUTE SHEET THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A recombinant fusion protein, resulting from the expression of two genes regulated by a single promoter, wherein the first of said genes codes for the rI rn hiin of a hiahly antigenic, hydrophilic protein nl WO 90/02187 PCT/EP89/01013 albumin and presented in Freund's Complete Adjuvant, to induce an immune response. Immunoneutralization of hypothalamic LHRH can be employed as a routine procedure to induce an infertile state characterized by low circulating levels of gonadotropins and S. gonadal steroids and anovulation or azospermia.
The production of antibodies against LHRH by active immunization is uncomfortable, if not painful, to the animal.
Although this method would induce a state of infertility and reduce behavioral heat (due to low circulating gonadal steroids) it could not be employed as a pet contraceptive.
There is a serious over-population of cats and dogs in the United States which is of great concern to the general public, animal welfare organizations, veterinarians, and health officials.
In the feline population, the reproductive rate has been reported to be almost twice the rate at which homes become available for these animals (Shreider and Vaida. J Am Vet Med Assoc. 166 481, 1975). To halt the growth of the feline population, approximately 88% of reproductively competent females should be spayed (Nassar and Masier, Am J Vet Res. 43:167, 1982). Approximately 20% of the dog population in the United States passes through an animal shelter each year and of that, approximately 80% of these animals are destroyed. The cost of impounding and destroying unwanted cats and dogs ranges from $125 to $500 million per year (Am.
Humane Society: Proceedings on Ecology of the Surplus Cat and Dog Problem).
SUBSTITUTE
SHEET
luteinizing hormone releasing hormone protein is expressed having antigenic characteristics.
DNA according to claim 8 or 9 wherein said second gene is inserted into one or more regions of said WO 90/02187 PCT/EP89/01013, At present, the only solutions to the problem of unwanted pregnancies in the dog and cat population are complete confinement and surgical gonadectomy. Neither method may be considered effective as a means of birth control. confinement does not reduce behavioral problems associated with heat and neutering clinics do not reach sufficient numbers of animals to alleviate the over-population problem. Costs of skilled professionals to perform the surgery, anesthesia, antibiotics and postoperative care are beyond the means of many pet owners.
It is an object of the present invention to provide a recombinant fusion protein or vaccine which provides an effective, safe, available and reversible means of fertility control. A vaccine that is easily administered is likely to supplant surgical sterilization while providing an effective contraceptive for dogs, cats and other mammals.
Pregnant cows typically do not exhibit an attractive feed to meat conversion since the developing fetus requires great nutritional requirements. As a result, feed loL owners generally pay substantially less for a cow in which the pregnancy status is unknown or unconfirmed. A certain percentage of cows enter the feed lot pregnant and the fetus represents waste. Thus, a method to induce an infertile state in cows 6-10 months prior to shipment is considered to be a viable, valuable product. If the farmer could guarantee that his cattle are "barren" he could command a higher price for his animals.
I
SUBSTITUTE
SHEET
CCI
WO 90/02187 PCT/EP89/01013 6 It is, therefore, another object to provide a recombinant, injectable product which would result in inhibition of ovulatory cyclicity in feedlot heifers.
There are many examples of human hormonally-mediated tissue hyperplasia. In the male, it is well known that prostatic carcinoma (BPH) is dependent upon testicular testosterone for continued growth. It would be advantageous to reduce serum levels of gonadotropins to inhibit gonadal steroid secretion and thus induce involution of hyperplastic tissue. It has recently been reported that a long-acting LHRH antagonist may be used in the treatment of prostatic hyperplasia (Peters and Walsh, New England Journal Medicine 317:599, 1987). The mechanism of action of this treatment is the inhibition of LH and FSH secretion by down-regulation of pituitary LHRH receptors. This results in an inhibition of gonadotropin secretion which causes a fall in testosterone production. A reduction in serum testosterone causes a regression of the prostatic hyperplasia. The authors note, however, that inhibition of LH secretion as elicited by injection of an LHRH antagonist would be required for prolonged periods of time, thus necessitating repeated administration.
It is yet another object of the present invention to avoid injections of LHRH antagonists to inhibit gonadotropin secretion, immunoneutralization of endogenous LHRH.
It is still a further object of the present invention to provide a method to make any substantially non-antigenic peptide highly immunogenic, preferably without the necessity of use of adjuvants such as Freund's Complete Adjuvant.
SUBSTITUTE
SHET
WO 90/02187 PCT/EP89/01013 FIG 1 Summary of the Invention In accordance with the principles and objectives of the present invention, there are provided methods for creating fusion proteins that may be employed as potent immunogens. Specifically, the present invention provides a recombinant fusion protein, resulting from the expression of two genes regulated by a single promoter, wherein the first of said genes codes for the production of a highly antigenic, hydrophilic protein and the second of said genes codes for a peptide which alone is substantially non-antigenic, or for a portion of such a peptide. The present invention further provides DNA encoding for the fusion protein comprising said two genes, a transcriptional initiation region, a promotor and an expression vector, said DNA capable of transforming mammalian cells to express the fusion protein. Ideally this i 2 0 I e :i VF PCT/EP89/01013 WO 90/02187 FIG 2 o ee* WO 90/02187 PCT/EP89/01013 Ii Summary of the Invention In accordance with the ri es and objectives of the present invention, are provided methods for creating fusion prot that may be employed as potent immunogens. Ideally, this method of the present invention employs molecular biology techniques to fuse cDNAs together, and to place them into a eukaryotic expression vector for the production of unique fusion proteins.
The majority of this fusion protein is a highly antigenic and potent immunogen. It should have substantial hydrophilicity.
Good examples of such immunogens are coat proteins such as the hepatitis B surface antigen. An oligonucleotide coding for the peptide of interest, against which it is desired to raise antibodies, such as the luteinizing hormone releasing hormone molecule, is placed in one or more regions of the protein, preferably in the one or more regions having the highest hydrophilicity.
Injection of the resultant protein, most preferably an LHRH-HBsAg fusion protein, in therapeutically effective concentration, will result in the development of antibodies against the entire molecule. A portion of these antibodies will be directed against the peptide of interest. Most preferably, when the peptide is LHRH, sufficient titres of antibodies against LHRH will be provided thereby preventing hypothalamic-pituitary communication and inducing an infertile state. This immunogen may also be advantageously employed in a variety of commercial or therapeutic settings including i.n animal anti-fertility vaccine and treatment for benign prostatic hypertrophy.
SUBSTITUTE
SHEET
I^
II
III
WOo 90/02187 PCT/EP89/01013 WO 90/02187 PCT/EP89/01013 The fusion proteins of the present invention are sufficiently immunogenic so as'to preclude the necessity of use of adjuvants or multiple injection, neither of which are well tolerated by the subject.
Brief Description of the Drawings Figure 1. Illustrates the insertion of gonadotropin releasing hormone sequences within the exposed hydrophilic region of HBsAg protein. At the top is a diagram of the HBsAg protein in which the site containing the LHRH decapeptide is stippled. Below that is the Aval site along the cDNA that codes for HBsAg in which the cDNA for LHRH is ideally inserted. The figure at the bottom represents a viral coat particle with LHRH inserted between the coat protein sequences.
Figure 2. Illustrates a synthetic DNA linker that will be inserted into the Aval site of the HBsAg (see Fig. This linker provides a flexible insertion site for oligonucleotide sequences after amino acid 119 (glycine) of the HBsAg. It results in the insertion of three amino acids before the resumption of the HBsAg sequence at the proline residue (position 120). The LHRH fragment is preferably inserted between the SmaI and BqlII site of the linker. Addition of the linker will maintain the proper reading frame (see Fig. 3).
SUBSTITUTE
SHEET
PCT/EP89/0101 3 WO 90/02187 FIG 4 Metalothionein promoter i WO 90/02187 PCT/EP89/01013 8 FiGure 3.
Figure 4.
Shows the nucleotide sequence for the LHRH peptide to be inserted in the synthetic linker within the HBsAg cDNA.
To maintain the proper reading frame, two additional nucleotides (GG) have been added to the 3' end of the oligonucleotide which will add a glycine (GGG) immediately following the inserted LHRH peptide and maintain the proper reading frame. Note the GG added to the 3' end to maintain the proper reading frame when inserted into the synthetic DNA linker (Figure We have also added the BglII overhang for proper insertion into the cut linker.
Diagrams the scheme used to insert HBsAg-LHRH fusion into mouse metallothionein promoter (CL28 vector) and subsequent insertion of the BPV genome. The plasmid EPV-HL is advantageously used to transform C127 cells.
Detailed Description of the Invention and Best Mode The gene encoding for the hepatitis B surface antigen has already been cloned and expressed (Hsiung et al., J. Mol.
Appl. Gen. 2:497, 1984). This gene is advantageously expressed in our mammalian expression system. The DNA encoding the coat protein was cloned into the mouse metallothionein gene, just a few base pairs from the site of transcription initiation. All of the signals that regulate the expression of the inserted gene (for coat protein) in mammalian cells are supplied by the mouse gene, whose coding sequences and poly A addition signals lie downstream from the insert. The surface antigen protein is secreted ibto the SUBSTITUTE
SHEET
i WO 90/02187 PCT/EP89/01013 medium where it is found in the form of particles. The recombinant product surface antigen without nuclear material) has been shown to be highly immunogenic in guinea pigs.
From the DNA sequence, the amino acid sequence of the hepatitis antigen was determined. This sequence was analyzed for the region of the molecule that would be expected to have the most hydrophilic properties. Into that region (identified by the AvaII site in Figure 1) was cloned a short oligonucleotide sequence that provides unique cloning sites (Figure Into this region, cDNA sequences encoding for specific proteins may be inserted either by blunt end ligation at a unique Smal site or at the BqlII site (see Figure 2).
Using the published structure of the hypothalamic gene (Seeburg and Adelman: Nature 311:666, 1984: Figure 3) but modified as described above, the oligonucleotide encoding LHRH was s-nthesized on an Applied Biosystems 380-A automated DNA synthesizer using the solid phase synthetic methods developed by Caruthers et al (Genetic Engineering 4:1-17, 1982). The oligonucleotide was cleaved from the solid support using concentrated am.nonium hydroxide. Purification was achieved using preparative gel electrophoresis. The purified oligonucleotide was polynucleotide kinase and analyzed by gel electrophoresis for size and purity.
The LHRH oligonucleotide was inserted into the SmaI and BagII cloning site by the following method: The LHRH oligonucleotide was synthesized (as shown in Figure 3) to contain a 3' blunt end and a 5' CTAG overhang. Folloving digestion of the HBsAg DNA (containing the synthetic insert) with Sma I and BqlII, the LHRH SSUBSTITUTE SHEET I I INTERNATIONAL SEARCH REPORT Internatlonal Apolicatlon No PCT/EP 89/01013 1. CLASSIFICATION OF SUBJECT MATTER (It several clasinc3ilon symbols aocly. Indicate all) Accotding to Intlrnatlonal Patont Classlicallon (IPC) or to both National Clasaificatlon and IPC C 12 N 15/62, 15/16 A 61 K 39/385 WO 90/02187 PCT/EP89/01013 DNA was inserted. The resultant construction was named HBsAg- LHRH. Synthetic BamHI linkers were added to each terminus of the HBsAg-LHRH cDNA and inserted into the vector CL28/Bam in the proper orientation. CL28/Bam obtained from Dr. Dean Hamer (at the NIH) contains a 3.8 kbp mouse DNA fragment that includes the entire metallothionein gene, including upstream control elements, inserted into the EcoRI site of the bacterial vector pBR322.
CL28/Bam is a derivative of pJYMMT(E) (Hamer, Dean et al, J. Mol.
Appl. Genet. 1, 4, 273-288 (1982)) which is identical to pJYMMT(E) except for the removal of the SV40 sequences. A unique BcrlII site located just after the transcriptional initiation region of the mouse gene allows the insertion of foreign genes as BamHI fragments which have the same 5' overhang (GATC) as the cut BglII site. Following the insertion of the HBsAg-LHRH fusion gene into CL28/Bam and endonuclease verification of orientation by the proper restriction pattern (with respect to the murine promoter) the entire genome of Bovine Papilloma virus (BPV) was inserted as a 7.B kbo BamHI-Sall fragment. The final construction was verified by examination of diagnostic restriction enzyme digestion patterns on both agarose and polyacrylamide gels. A schematic representation of this method is provided in Figure 4.
Thus, the resultant hepatitis B surface protein contained an LHRH sequence within a hydrophilic region of the !I molecule.
To produce a cell line that expresses the fusion HBsAg/LHRH protein, 10pg of the purified BPV-HBsAg-LHRH cDNA was added to 0.5 ml of a 250mm CaCl 2 solution containing 10g salmon f SUBSTITUTE SHEET international Aollicatlon No. PCT/EP 89/01013 III, DOCUMENTS CONSIDERED TO LE RELEVANT (CONTINUED FROM THE SECOND SHEET) Category Citation of Docunmnt, with indicatlon., w.e saproonate. of the reivlt passage Relevant to Claim No I y FD nI 111 f z trci TItr', i TTI- WO 90/02187 PCT/EP89/01013 sperm DNA as a carrier. The mixture was bubbled into 0.5ml of 28mM NaC1, 50mM HEPES and 1.5mM sodium phosphate. The calcium phosphate precipitate was allowed to form for 30-40 minutes at room temperature.
Twenty-four hours prior to transfection, 5 x 105 mouse C127 cells were placed into 100mM petri dish. Immediately before adding the exogenous DNA, cells were fed with fresh medium (Dulbecco's modified Eagle's medium plus 10% fetal calf serum). One ml of calcium phosphate precipitate were added to each dish and the cells incubated for 6-8 h at 37"C.
Medium was aspirated and replaced with 5ml of 20% glycerol in phosphate buffered saline (pH 7.0) for 2 min. at room temperature. Cells were washed with phosphate buffered saline, fed with 10ml medium and incubated at 37'C. After 20-24 hours, medium was changed and cells refed every 3-4 days.
After 14-21 days, foci of transformed cells, characterized by their altered morphology, were identified and transferred to T-25 flasks to begin line expansion. Medium obtained from the cell lines was tested for presence of HBsAg and LHRH immunoactivity. Tissue culture medium was clarified by low speed centrifugation and HBsAg particles were sedimented at 42,000 rpm (200,000 xg) for 4 hours. Pellets were resuspended in a small volume of phosphate-b'ffered saline and assayed along with starting material and supernatants for HBsAg activity with a commercial radioimmunoassay (RIA) purchased from Clinical Assays, Inc. The culture medium supernatants and resuspended pellets were analyzed for LHRH immunoactivity with a radioimmunoassay utilizing LHRH antiserum SUBSTITUTE
SHEET
ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/EP 89/01013 ZAI -7 C WO 90/02187 PCT/EP89/01013 purchased from Arnel Antibodies, Inc. The LHRH for iodination and the reference preparation were purchased from Sigma Fine Chemicals, Inc., and the insoluble protein A (to pellet antigenantibody complexes) was obtained from Sigma Fine Chemicals, Inc.
Following these procedures, cell lines expressing the fusion protein were produced and readily identified by standard screening methods. With a few milligrams of purified material, the appropriate dose to elicit an infertile state in male rabbits or other animals may be determined with a titration type procedure. For example, male rabbits injected with 0.5, 1 or 5 mg of the protein coupled with blood sample collection will allow determination of serum gonadotropin and testicular steroid levels as well as anti-LHRH antibody titres. Similarly, appropriate boosting intervals may also be determined.
From the foregoing, those skilled in the art will raadily determine that numerous modifications can be made to the fusion genes and gene products such as the selection of the antigenic gene or the protein gene whose activity is to be immunologically suppressed, without departing from either the spirit or scope of the present invention. For example, highly immunogenic proteins other than HBsAg may be used, such as other hydrophilic coat proteins or the hepatitis B core antigen. Furthermore, those skilled in the art will understand that peptides other than LHRH may be used. While a similar method has been reported for presenting antigenic epitopes to the immune system, in Australian patent 69792/87, antigenic apitopes are always used, such as viral, bacterial or protozoan epitopes. It has not before been SUBSTITUTE
SHEET
I wWO 90/02187 s~ JI PCT/EP89/01013 suggested to use non-antigenic peptides in such a fusion protein in order to be able to induce the production of antibodies against such peptides without the disadvantages of prior art haptenization techniques.
Examples of substantially non-antigenic peptides are peptides which do not substantially differ in structure across species or any other peptide or protein which, when injected into a foreign animal, does not cause any substantial titre of antisodies to be raised against it. Besides LHRH, there may be mentioned growth hormone releasing hormone, adrenocorticotropin hormone, parathyroid hormone, inhibin, and subunits of gonadotropins. Portions of or slightly modified versions of such peptides may also be used.
SUBSTITUTE
SHEET
Claims (9)
- 2. A fusion protein according to Claim 1 wherein the fusion protein is highly antigenic and causes the production of antibodies which include antibodies against said substantially non-antigenic peptide.
- 3. A fusion protein according to Claim 1 or 2 wherein said peptide comprises a hormone and the antibodies produced can immuno-neutralize the same hormone endogenously produced.
- 4. A fusion protein according to any one of Claims S 1-3 wherein said highly antigenic, hydrophilic protein is hepatitis surface antigen. -0 5. A fusion protein according to any one of Claims 1-4 wherein the second gene encodes for a protein having hormonal activity substantially similar to the activity of an endogenously produced hormone.
- 6. A fusion protein according to Claim 5 wherein said second gene encodes for luteinizing hormone releasing hormone.
- 7. A fusion protein according to any one of claims 1-6 wherein said second gene is inserted into one or more S regions of said first gene, each of said regions encoding a highly hydrophilic region of said protein.
- 8. DNA encoding for the fusion protein of any one of Claims 1-7 comprising said two genes, a transcriptional initiation region, a promotor and an expression vector, said DNA capable of transforming mammalian cells to express the fusion protein.
- 9. DNA according to Claim 8 comprising DNA encoding for HBsAg-LHRH protein fused ith a mouse metallothionein promoter and a bovine papilloma virus 39 genome in proper sequence and reading frame whereby a AL1,14;~ luteinizing hormone releasing hormone protein is expressed having antigenic characteristics. DNA according to claim 8 or 9 wherein said second gene is inserted into one or more regions of said first gene, each of said regions encoding a highly hydrophilic region of said protein.
- 11. A recombinant fusion protein according to claim 1 substantially as hereinbefore described.
- 12. DNA according to claim 8 substantially as hereinbefore described. DATED: 5 June 1992 PHILLIPS ORMONDE FITZPATRICK Attorneys for: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. e *0 *o*
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24655888A | 1988-08-30 | 1988-08-30 | |
US246558 | 1988-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4076189A AU4076189A (en) | 1990-03-23 |
AU629237B2 true AU629237B2 (en) | 1992-10-01 |
Family
ID=22931196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU40761/89A Ceased AU629237B2 (en) | 1988-08-30 | 1989-08-29 | Recombinant fusion proteins for altering hormone secretion |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0396653A1 (en) |
JP (1) | JPH03502584A (en) |
AU (1) | AU629237B2 (en) |
DK (1) | DK106590A (en) |
FI (1) | FI902151A0 (en) |
GR (1) | GR1000321B (en) |
IL (1) | IL91462A0 (en) |
WO (1) | WO1990002187A1 (en) |
ZA (1) | ZA896628B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448513A3 (en) * | 1990-03-21 | 1991-12-27 | Japat Ltd | Process for production of peptidylglycine alpha-hydroxylating monooxygenase and use thereof |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
JPH05339295A (en) * | 1991-12-05 | 1993-12-21 | Agency Of Ind Science & Technol | Preparation of antibody |
US5688506A (en) * | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
ATE286511T1 (en) * | 1999-02-17 | 2005-01-15 | Pfizer Prod Inc | FUSION PROTEINS WITH CARRIERS THAT INDUCE A DOUBLE IMMUNE RESPONSE |
EP1303533A2 (en) | 2000-05-05 | 2003-04-23 | Aphton Corporation | Chimeric peptide immunogens, their preparation and use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963691A (en) * | 1974-10-07 | 1976-06-15 | Merck & Co., Inc. | Synthetic antigens of luteinizing hormone releasing hormone |
GB8314362D0 (en) * | 1983-05-24 | 1983-06-29 | Celltech Ltd | Polypeptide and protein products |
ATE70308T1 (en) * | 1984-09-12 | 1991-12-15 | Chiron Corp | HYBRID PARTICLE IMMUNOGENS. |
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
AU5993186A (en) * | 1985-06-04 | 1987-01-07 | Biotechnology Research Partners Limited | Autoantigen vaccines |
GB8525615D0 (en) * | 1985-10-17 | 1985-11-20 | Hoffmann La Roche | Polypeptides |
-
1989
- 1989-08-29 JP JP1508969A patent/JPH03502584A/en active Pending
- 1989-08-29 EP EP89909550A patent/EP0396653A1/en not_active Withdrawn
- 1989-08-29 IL IL91462A patent/IL91462A0/en unknown
- 1989-08-29 WO PCT/EP1989/001013 patent/WO1990002187A1/en not_active Application Discontinuation
- 1989-08-29 AU AU40761/89A patent/AU629237B2/en not_active Ceased
- 1989-08-30 ZA ZA896628A patent/ZA896628B/en unknown
- 1989-08-30 GR GR890100540A patent/GR1000321B/en unknown
-
1990
- 1990-04-27 FI FI902151A patent/FI902151A0/en not_active IP Right Cessation
- 1990-04-30 DK DK106590A patent/DK106590A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK106590D0 (en) | 1990-04-30 |
ZA896628B (en) | 1991-04-24 |
GR890100540A (en) | 1990-08-22 |
WO1990002187A1 (en) | 1990-03-08 |
IL91462A0 (en) | 1990-04-29 |
DK106590A (en) | 1990-04-30 |
JPH03502584A (en) | 1991-06-13 |
FI902151A0 (en) | 1990-04-27 |
AU4076189A (en) | 1990-03-23 |
GR1000321B (en) | 1992-06-25 |
EP0396653A1 (en) | 1990-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jones et al. | Phase I clinical trial of a World Health Organisation birth control vaccine | |
US6087352A (en) | Use of Zeranol to modulate reproductive cycles | |
CA2255888A1 (en) | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | |
US20210054041A1 (en) | Glycoprotein Hormone Long-Acting Superagonists | |
AU2017431494A1 (en) | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof | |
Zhang et al. | Development of recombinant ovalbumin-luteinizing hormone releasing hormone as a potential sterilization vaccine | |
WO1991016922A1 (en) | Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity | |
AU629237B2 (en) | Recombinant fusion proteins for altering hormone secretion | |
JP3959746B2 (en) | Improved peptides, immunogenic compositions and vaccines or pharmaceutical formulations, methods of immunizing animals against LHRH hormones, and LHRH tandem repeat peptides and their use as vaccines | |
CA1330420C (en) | Compositions containing growth hormone peptide fragments | |
JPH05500654A (en) | Contraceptive vaccine based on cloned zona pellucida gene | |
US20020107187A1 (en) | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | |
JPH03503403A (en) | biologically active molecules | |
CN100522994C (en) | Discrimination between GnRH-I and GnRH-II | |
JP2899534B2 (en) | Method of inducing superovulation in cattle | |
JPS63503141A (en) | How to regulate reproductive function in animals | |
McCauley et al. | Manipulation of endogenous hormones to increase growth of pigs | |
JP2000508293A (en) | Novel peptide useful for promoting FSH action | |
US5212156A (en) | Srif-related peptides and uses thereof | |
Barkley | Evidence for maternal regulation of progesterone production at midpregnancy in the mouse | |
Scaramuzzi et al. | The implications of immunological techniques for the improvement of production efficiency in pigs. | |
AU738528B2 (en) | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof | |
CN115991792A (en) | Long-acting recombinant LH fusion protein and preparation method and application thereof | |
Chang | THE REGULATION OF REPRODUCTION IN CATTLE BY AN ANTIESTROGEN, OR ACTIVE IMMUNIZATION AGAINST PROSTAGLANDIN F (2ALPHA) AND OVARIAN STEROIDS | |
Cytoskeleton | Hsp90 and S1.(A) SDS-PAGE analysis of S1 (10 M) and/or Hsp90 (1 M) interacting with UNC-45 (1 M) at 30 C for 30 min.(B) The aggregation of S1 (1.0 M) at 43 C was measured by light scattering (320 nm)(11) with no additional protein (solid circles), 2.0 M bovine serum albumin (open circles), 0.5 M UNC-45 (squares), 1.0 M UNC-45 (diamonds), or 2.0 M UNC-45 (triangles). |